OMNICELL INC
OMCLNASDAQTrading Snapshot
- Day Range
- $35.45 β $37.50
- 52-Week Range
- $29.09 β $55.00
- Volume (shares)
- 936,895
- Avg Volume (shares)
- β
- Shares Outstanding
- 45.6M
- Next Earnings
- 2026-10-29
Fundamentals Snapshot
- Annual Revenue
- $1.18B
- Last Q Revenue
- $312M
- P/E Ratio
- 43.1
- P/S Ratio
- 1.4x
- EPS (TTM)
- $0.85
- Dividend Yield
- β
- Dilution (1yr)
- β2.8%
OMNICELL INC
OMCLAbout OMNICELL INC
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.

Financial Contrast: Baxter International (NYSE:BAX) and Omnicell (NASDAQ:OMCL)
Omnicell (NASDAQ: OMCL - Get Free Report) and Baxter International (NYSE: BAX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of

Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026.

Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Omnicell (OMCL) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.